HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
Fair value lifts for toll road operator as Aussie fuel supply steadies
stocks
Wide moat stock exchange remains cheap
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.80 | 23.20 | 0.26% |
| CAC 40 | 8,123.73 | 59.61 | -0.73% |
| DAX 40 | 24,989.13 | 115.57 | -0.46% |
| Dow JONES (US) | 50,891.65 | 140.81 | -0.28% |
| FTSE 100 | 10,321.89 | 87.39 | -0.84% |
| HKSE | 25,398.18 | 215.79 | 0.86% |
| NASDAQ | 27,013.29 | 40.67 | 0.15% |
| Nikkei 225 | 66,934.33 | 604.83 | 0.91% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,579.43 | 0.63 | -0.01% |
| S&P/ASX 200 | 8,729.40 | 19.40 | 0.22% |
| SSE Composite Index | 4,057.74 | 10.83 | -0.27% |